Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule Type, By Product, By Type, By Disease, By Formulation, By Age Group, By Route Of Administration, By End Market, By Region, And Segment Forecasts, 2023 - 2030

Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule Type, By Product, By Type, By Disease, By Formulation, By Age Group, By Route Of Administration, By End Market, By Region, And Segment Forecasts, 2023 - 2030


Pharmaceutical Market Growth & Trends

The global pharmaceutical market size is expected to reach USD 2,363.25 billion by 2030, expandingat a CAGR of 6.12% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the pharmaceuticals market is attributable to the increasing prevalence of chronic diseases, leading to a growing need for developing novel therapeutics. According to the National Council on Aging, it is estimated that approximately 95% of the older population has at least one chronic ailment, and around 80% has two or more. Moreover, chronic diseases such as diabetes, arthritis, and heart disease disproportionately affect the elderly population.

Awareness is critical for prevention, early detection, focused therapy, and effective treatment. People aware of an illness and its symptoms are more inclined to take preventative measures, such as screenings, tests, and check-ups. The increased awareness of various diseases is another element driving the pharmaceutical space. As people are now aware of diseases such as cancer and diabetes, they are more likely to seek treatment if they develop those conditions. A number of initiatives are taken by public and private organizations to spread awareness and educate the population. Furthermore, many people now have insurance policies that cover prescription drug expenses, contributing to increased pharmaceutical demand.

Moreover,the demand for pharmaceuticals is significantly increasing globally due to advancements in technology in the development of novel therapeutics. The pharmaceutical industry invests at an unprecedented rate in research and development, as well as product sales and distribution. The industry focuses on distinctly and directly addressing people's health. The pharmaceuticals industry is critical to patient care and community development and provides numerous life-saving treatments, generates employment, and contributes to the world economy.

Many biological agents, such as bacteria and viruses, are used in vaccine manufacturing, fermentation processes, and biotechnology. The market is made up of a diverse spectrum of companies, including giant pharma, mid-sized specialty, virtual pharma, generic manufacturers, and small biotechnology and biopharmaceutical organizations. Furthermore, key players involved in developing and formulating various therapeutic formulations are focusing on collaborations and partnerships to develop novel medications and maintain their competitive position in the market.

Moreover, several players are involved in developing novel pharmaceuticals to meet the rising demand for the prevention and treatment of conditions. For instance, in April 2023 , F. Hoffmann-La Roche Ltd. announced that its wet age-related macular degeneration drug, Vabysmo, which received FDA approval in January 2022 , brought around USD 500 million during the first quarter of 2023. The drug's sales increased by more than 500% year-on-year, beating competitors such as multiple sclerosis treatment Ocrevus and the hemophilia medication Hemlibra. Moreover, in July 2023, Novartis AG received U.S. FDA approval for an expanded indication of Leqvio (inclisiran), in order to include treatment of patients with high LDL-C who are at an increased risk of heart diseases.

Pharmaceutical Market Report Highlights
  • Based on molecule type, conventional drugs (small molecules) dominated the overall market. Conventional drugs’ dominance in the pharmaceuticals market is due to their well-established manufacturing processes, predictable pharmacokinetics, and oral bioavailability
  • Based on product, the branded segment held the largest revenue share in the pharmaceuticals market in 2022, owing to the presence of several giant pharmaceutical players in the market specializing in branded medication since a long time
  • Based on type, OTC pharmaceuticals are expected to showcase the fastest growth rate over the forecast period owing to the ease of procurement of medication through this channel aided by the reduced need to visit a physician
  • In terms of disease, cancer dominated the pharmaceuticals market in 2022. The dominance of the cancer segment in the market can be attributed to several key factors such as the rising global incidence of various types of cancer, increased demand for innovative & effective treatments, and significant investments and research in this area
  • On the basis of formulation, tablets held the largest revenue share in the pharmaceuticals market in 2022, owing to the ease of administration and greater adoption of this formulation
  • In terms of route of administration, the oral route of administration segment dominated the global market in 2022
  • Based on age group, the adult segment is expected to show fastest growth over the forecast period, owing to the dominance of the adult population globally in the patient pool that consumes various pharmaceuticals
  • In terms of the end market, hospitals dominated the pharmaceuticals industry, underscored by the escalating healthcare demands due to an aging population, increased prevalence of chronic illnesses, and advancements in medical treatments
  • North America held the largest revenue share in 2022, which can be attributed to the developed regional healthcare infrastructure, growing cases of chronic diseases, presence of several key players, and availability of proper and innovative medications in the region
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Pharmaceutical Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Pharmaceutical Market: Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Pharmaceutical Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Dynamics
3.2.1. Market Drivers Analysis
3.2.1.1. Increasing healthcare spending by the government
3.2.1.2. Improving affordability driven by rising per capita income
3.2.1.3. Increasing awareness about healthcare among the population
3.2.1.4. Increasing access to innovative and modern medicines
3.2.1.5. Demographic and lifestyle changes leading to rising prevalence of chronic diseases
3.2.1.6. Rising chronic diseases and geriatric population
3.2.2. Market Restraint Analysis
3.2.2.1. COVID - 19 pandemic
3.2.2.2. Intensification of competition from generic and biosimilar drugs
3.2.2.3. Increasing price - sensitivity of customers for non - reimbursed drugs
3.2.2.4. Increasing barriers to market access and decreasing R&D productivity of pharma companies
3.3. Porter’s Five Forces Analysis
3.4. PESTLE Analysis
Chapter 4. Pharmaceutical Market: Molecule Type Outlook Estimates & Trend Analysis
4.1. Molecule Type Outlook: Movement Analysis
4.2. Biologics & Biosimilars (Large Molecules)
4.2.1. Biologics & Biosimilars Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
4.2.1.1 Monoclonal Antibodies
4.2.1.2 Monoclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
4.2.2.3 Vaccines
4.2.2.4 Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
4.2.3.5 Cell & Gene Therapy
4.2.3.6 Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
4.2.4.7 Others
4.2.4.8 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
4.3. Conventional Drugs (Small Molecules)
4.3.1. Conventional Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
Chapter 5. Pharmaceutical Market: Product Estimates & Trend Analysis
5.1. Pharmaceutical Market: Product Movement Analysis
5.2. Branded
5.2.1. Branded Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.3. Generic
5.3.1. Generic Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 6. Pharmaceutical Market: Type Estimates & Trend Analysis
6.1. Pharmaceutical Market: Type Movement Analysis
6.2. Prescription
6.2.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.3. OTC
6.3.1. OTC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 7. Pharmaceutical Market: Diseases Outlook Estimates & Trend Analysis
7.1. Pharmaceutical Market: Diseases Outlook Movement Analysis
7.2. Cardiovascular diseases
7.2.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3. Cancer
7.3.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4. Diabetes
7.4.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Infectious diseases
7.5.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6. Neurological disorders
7.6.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7. Respiratory diseases
7.7.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8. Autoimmune diseases
7.8.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.9. Mental health disorders
7.9.1. Mental Health Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.10. Gastrointestinal disorders
7.10.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.11. Women’s Health Diseases
7.11.1. Women’s Health Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.12. Genetic and Rare genetic diseases
7.12.1. Genetic and Rare Genetic Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.13. Dermatological conditions
7.13.1. Dermatological Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.14. Obesity
7.14.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.15. Renal diseases
7.15.1. Renal Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.17. Liver conditions
7.17.1. Liver Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.17. Hematological disorders
7.17.1. Hematological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.18. Eye conditions
7.18.1. Eye Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.19. Infertility conditions
7.19.1. Infertility Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.20. Endocrine disorders
7.20.1. Endocrine Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.21. Allergies
7.21.1. Allergies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.22. Others
7.22.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 8. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis
8.1. Pharmaceutical Market: Route of Administration Movement Analysis
8.2. Oral
8.2.1. Oral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.3. Topical
8.3.1. Topical Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.4. Parenteral
8.4.1. Parenteral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.4.1.1. Intravenous
8.4.1.2. Intramuscular
8.5. Inhalations
8.5.1. Inhalations Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.6. Other
8.6.1. Other Routes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 9. Pharmaceutical Market: Formulation Estimates & Trend Analysis
9.1. Pharmaceutical Market: Formulation Movement Analysis
9.2. Tablets
9.2.1. Tablets Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
9.3. Capsules
9.3.1. Capsules Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
9.4. Injectable
9.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
9.5. Sprays
9.5.1. Sprays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
9.6. Suspensions
9.6.1. Suspensions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
9.7. Powders
9.7.1. Powders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
9.8. Other Formulations
9.8.1. Other Formulations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 10. Pharmaceutical Market: Age Group Estimates & Trend Analysis
10.1. Pharmaceutical Market: Age Group Movement Analysis
10.2. Children & Adolescents
10.2.1. Children & Adolescents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
10.3. Adults
10.3.1. Adults Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
10.4. Geriatric
10.4.1. Geriatric Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 11. Pharmaceutical Market: End Market Estimates & Trend Analysis
11.1. Pharmaceutical Market: End Market Movement Analysis
11.2. Hospitals
11.2.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
11.3. Clinics
11.3.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
11.4. Others
11.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 12. Pharmaceutical Market: Regional Business Analysis
12.1. Pharmaceutical Market Share By Region, 2022 & 2030
12.2. North America
12.2.1. North America Pharmaceutical market, 2018 - 2030 (USD Million)
12.2.2. U.S.
12.2.2.1. Key Country Dynamics
12.2.2.2. Target Disease Prevalence
12.2.2.3. Competitive Scenario
12.2.2.4. Regulatory Framework
12.2.2.5. Reimbursement Scenario
12.2.2.6. U.S. Pharmaceutical market, 2018 - 2030 (USD MILLION)
12.2.3. Canada
12.2.3.1. Key Country Dynamics
12.2.3.2. Target Disease Prevalence
12.2.3.3. Competitive Scenario
12.2.3.4. Regulatory Framework
12.2.3.5. Reimbursement Scenario
12.2.3.6. Canada Pharmaceutical market, 2018 - 2030 (USD Million)
12.3. Europe
12.3.1. Europe Pharmaceutical market, 2018 - 2030 (USD Million)
12.3.2. Germany
12.3.2.1. Key Country Dynamics
12.3.2.2. Target Disease Prevalence
12.3.2.3. Competitive Scenario
12.3.2.4. Regulatory Framework
12.3.2.5. Reimbursement Scenario
12.3.2.6. Germany Pharmaceutical market, 2018 - 2030 (USD Million)
12.3.3. UK
12.3.3.1. Key Country Dynamics
12.3.3.2. Target Disease Prevalence
12.3.3.3. Competitive Scenario
12.3.3.4. Regulatory Framework
12.3.3.5. Reimbursement Scenario
12.3.3.6. UK Pharmaceutical market, 2018 - 2030 (USD Million)
12.3.4. France
12.3.4.1. Key Country Dynamics
12.3.4.2. Target Disease Prevalence
12.3.4.3. Competitive Scenario
12.3.4.4. Regulatory Framework
12.3.4.5. Reimbursement Scenario
12.3.4.6. France Pharmaceutical market, 2018 - 2030 (USD Million)
12.3.5. Italy
12.3.5.1. Key Country Dynamics
12.3.5.2. Target Disease Prevalence
12.3.5.3. Competitive Scenario
12.3.5.4. Regulatory Framework
12.3.5.5. Reimbursement Scenario
12.3.5.6. Italy Pharmaceutical market, 2018 - 2030 (USD Million)
12.3.6. Spain
12.3.6.1. Key Country Dynamics
12.3.6.2. Target Disease Prevalence
12.3.6.3. Competitive Scenario
12.3.6.4. Regulatory Framework
12.3.6.5. Reimbursement Scenario
12.3.6.6. Spain Pharmaceutical market, 2018 - 2030 (USD Million)
12.3.7. Denmark
12.3.12.1. Key Country Dynamics
12.3.12.2. Target Disease Prevalence
12.3.12.3. Competitive Scenario
12.3.12.4. Regulatory Framework
12.3.12.5. Reimbursement Scenario
12.3.12.6. Denmark Pharmaceutical market, 2018 - 2030 (USD Million)
12.3.8. Sweden
12.3.8.1. Key Country Dynamics
12.3.8.2. Target Disease Prevalence
12.3.8.3. Competitive Scenario
12.3.8.4. Regulatory Framework
12.3.8.5. Reimbursement Scenario
12.3.8.6. Sweden Pharmaceutical market, 2018 - 2030 (USD Million)
12.3.9. Norway
12.3.9.1. Key Country Dynamics
12.3.9.2. Target Disease Prevalence
12.3.9.3. Competitive Scenario
12.3.9.4. Regulatory Framework
12.3.9.5. Reimbursement Scenario
12.3.9.6. Norway Pharmaceutical market, 2018 - 2030 (USD Million)
12.4. Asia Pacific
12.4.1. Asia Pacific Pharmaceutical market, 2018 - 2030 (USD Million)
12.4.2. Japan
12.4.2.1. Key Country Dynamics
12.4.2.2. Target Disease Prevalence
12.4.2.3. Competitive Scenario
12.4.2.4. Regulatory Framework
12.4.2.5. Reimbursement Scenario
12.4.2.6. Japan Pharmaceutical market, 2018 - 2030 (USD Million)
12.4.3. China
12.4.3.1. Key Country Dynamics
12.4.3.2. Target Disease Prevalence
12.4.3.3. Competitive Scenario
12.4.3.4. Regulatory Framework
12.4.3.5. Reimbursement Scenario
12.4.3.6. China Pharmaceutical market, 2018 - 2030 (USD Million)
12.4.4. India
12.4.4.1. Key Country Dynamics
12.4.4.2. Target Disease Prevalence
12.4.4.3. Competitive Scenario
12.4.4.4. Regulatory Framework
12.4.4.5. Reimbursement Scenario
12.4.4.6. India Pharmaceutical market, 2018 - 2030 (USD Million)
12.4.5. South Korea
12.4.5.1. Key Country Dynamics
12.4.5.2. Target Disease Prevalence
12.4.5.3. Competitive Scenario
12.4.5.4. Regulatory Framework
12.4.5.5. Reimbursement Scenario
12.4.5.6. South Korea Pharmaceutical market, 2018 - 2030 (USD Million)
12.4.6. Australia
12.4.6.1. Key Country Dynamics
12.4.6.2. Target Disease Prevalence
12.4.6.3. Competitive Scenario
12.4.6.4. Regulatory Framework
12.4.6.5. Reimbursement Scenario
12.4.6.6. Australia Pharmaceutical market, 2018 - 2030 (USD Million)
12.4.7. Thailand
12.4.7.1. Key Country Dynamics
12.4.7.2. Target Disease Prevalence
12.4.7.3. Competitive Scenario
12.4.7.4. Regulatory Framework
12.4.7.5. Reimbursement Scenario
12.4.7.6. Thailand Pharmaceutical market, 2018 - 2030 (USD Million)
12.5. Latin America
12.5.1. Latin America Pharmaceutical market, 2018 - 2030 (USD Million)
12.5.2. Brazil
12.5.2.1. Key Country Dynamics
12.5.2.2. Target Disease Prevalence
12.5.2.3. Competitive Scenario
12.5.2.4. Regulatory Framework
12.5.2.5. Reimbursement Scenario
12.5.2.6. Brazil Pharmaceutical market, 2018 - 2030 (USD Million)
12.5.3. Mexico
12.5.3.1. Key Country Dynamics
12.5.3.2. Target Disease Prevalence
12.5.3.3. Competitive Scenario
12.5.3.4. Regulatory Framework
12.5.3.5. Reimbursement Scenario
12.5.3.6. Mexico Pharmaceutical market, 2018 - 2030 (USD Million)
12.5.4. Argentina
12.5.4.1. Key Country Dynamics
12.5.4.2. Target Disease Prevalence
12.5.4.3. Competitive Scenario
12.5.4.4. Regulatory Framework
12.5.4.5. Reimbursement Scenario
12.5.4.6. Argentina Pharmaceutical market, 2018 - 2030 (USD Million)
12.6. MEA
12.6.1. MEA Pharmaceutical market, 2018 - 2030 (USD Million)
12.6.2. South Africa
12.6.2.1. Key Country Dynamics
12.6.2.2. Target Disease Prevalence
12.6.2.3. Competitive Scenario
12.6.2.4. Regulatory Framework
12.6.2.5. Reimbursement Scenario
12.6.2.6. South Africa Pharmaceutical market, 2018 - 2030 (USD Million)
12.6.3. Saudi Arabia
12.6.3.1. Key Country Dynamics
12.6.3.2. Target Disease Prevalence
12.6.3.3. Competitive Scenario
12.6.3.4. Regulatory Framework
12.6.3.5. Reimbursement Scenario
12.6.3.6. Saudi Arabia Pharmaceutical market, 2018 - 2030 (USD Million)
12.6.4. UAE
12.6.4.1. Key Country Dynamics
12.6.4.2. Target Disease Prevalence
12.6.4.3. Competitive Scenario
12.6.4.4. Regulatory Framework
12.6.4.5. Reimbursement Scenario
12.6.4.6. UAE Pharmaceutical market, 2018 - 2030 (USD Million)
12.6.5. Kuwait
12.6.5.1. Key Country Dynamics
12.6.5.2. Target Disease Prevalence
12.6.5.3. Competitive Scenario
12.6.5.4. Regulatory Framework
12.6.5.5. Reimbursement Scenario
12.6.5.6. Kuwait Pharmaceutical market, 2018 - 2030 (USD Million)
Chapter 13. Competitive Landscape
13.1. Company Categorization
13.2. Strategy Mapping
13.2.1. New Product Launch
13.2.2. Partnerships
13.2.3. Acquisition
13.2.4. Collaboration
13.2.5. Funding
13.3. Key Company Market Share Analysis, 2022
13.4. Company Heat Map Analysis
13.5. Company Profiles
13.5.1. F. HOFFMANN - LA ROCHE LTD.
13.5.1.1. Company Overview
13.5.1.2. Financial Performance
13.5.1.3. Product Benchmarking
13.5.1.4. Strategic Initiatives
13.5.2. NOVARTIS AG
13.5.2.1. Company Overview
13.5.2.2. Financial Performance
13.5.2.3. Product Benchmarking
13.5.2.4. Strategic Initiatives
13.5.3. ABBVIE INC.
13.5.3.1. Company Overview
13.5.3.2. Financial Performance
13.5.3.3. Product Benchmarking
13.5.3.4. Strategic Initiatives
13.5.4. JOHNSON & JOHNSON SERVICES, INC.
13.5.4.1. Company Overview
13.5.4.2. Financial Performance
13.5.4.3. Product Benchmarking
13.5.4.13. Strategic Initiatives
13.5.5. MERCK & CO., INC.
13.5.5.1. Company Overview
13.5.5.2. Financial Performance
13.5.5.3. Product Benchmarking
13.5.5.4. Strategic Initiatives
13.5.6. PFIZER INC.
13.5.6.1. Company Overview
13.5.6.2. Financial Performance
13.5.6.3. Product Benchmarking
13.5.6.4. Strategic Initiatives
13.5.7. BRISTOL - MYERS SQUIBB COMPANY
13.5.7.1. Company Overview
13.5.7.2. Financial Performance
13.5.7.3. Product Benchmarking
13.5.7.4. Strategic Initiatives
13.5.8. SANOFI
13.5.8.1. Company Overview
13.5.8.2. Financial Performance
13.5.8.3. Product Benchmarking
13.5.8.4. Strategic Initiatives
13.5.9. GSK PLC
13.5.9.1. Company Overview
13.5.9.2. Financial Performance
13.5.9.3. Product Benchmarking
13.5.9.4. Strategic Initiatives
13.5.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
13.5.10.1. Company Overview
13.5.10.2. Financial Performance
13.5.10.3. Product Benchmarking
13.5.10.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings